Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Zimmer Biomet and its executives [1] - Zimmer Biomet reported third-quarter 2025 net sales of $2 billion, which fell short of the consensus estimate of $2.01 billion [2] - The company revised its full-year organic revenue growth outlook down to a range of 3.5% to 4%, from a previous range of 3.5% to 4.5% [2] - Weakness in international markets and non-core businesses, along with order cancellations in the Middle East and Eastern Europe, negatively impacted results [2] - The stock price of Zimmer Biomet dropped by $15.63 per share, or 15.5%, closing at $87.55 on November 5, 2025, following the earnings announcement [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Gauzy Ltd. following the company's announcement of delayed financial results due to insolvency proceedings for its subsidiaries in France [1][2]. Group 1: Company Announcement - On November 14, 2025, Gauzy announced it would not release its third-quarter financial results as planned, citing a court-ordered commencement of insolvency proceedings for three subsidiaries in France [2]. - The stock price of Gauzy fell by $1.35 per share, or 33.58%, closing at $2.67 per share on the same day [2]. Group 2: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors of Gauzy to determine if the company and its officers engaged in securities fraud or other unlawful business practices [1].

Core Points - A class action lawsuit has been filed against Perrigo Company plc for alleged securities fraud and unlawful business practices [1] - Investors who purchased Perrigo securities during the Class Period can apply to be Lead Plaintiff by January 16, 2026 [2] - Perrigo reported significant financial challenges, including a 50% decline in earnings per share for fiscal year 2023 due to remediation costs in its infant formula business [2] - The company's stock price has experienced significant declines following negative earnings reports and strategic announcements, including a drop of 25.2% to close at $15.10 per share on November 5, 2025, after announcing a strategic review of its infant formula business [3] Financial Performance - For fiscal year 2023, Perrigo incurred one-time cash costs of $35 million to $45 million related to production issues in its infant formula business [2] - The adjusted gross profit for the second quarter ended June 28, 2025, decreased by $30 million, or 6.9%, attributed to production variability in infant formula [3] - The stock price fell by $4.87 per share (15.14%) on February 27, 2024, and by $3.28 per share (9.8%) on May 7, 2024, following negative earnings reports [2][3]

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for potential securities fraud and unlawful business practices following disappointing trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit is initiated by Pomerantz LLP, which is known for its expertise in corporate and securities class litigation [5]. - Investors who purchased MoonLake securities during the Class Period have until December 15, 2025, to request appointment as Lead Plaintiff [2]. Group 2: Company Performance - On September 28, 2025, MoonLake reported unsatisfactory results from its Phase 3 VELA trials for sonelokimab, with one trial failing to meet its primary endpoint and the other showing only modest improvements compared to placebo [4]. - Following the announcement of these results, MoonLake's stock price plummeted by $55.75 per share, a decrease of 89.93%, closing at $6.24 per share on September 29, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 29, 2024, to January 6, 2025, related to the company's merger with Koito Manufacturing Co., Ltd. [1] Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased or sold Cepton common stock during the specified Class Period [1] - Investors have until December 8, 2025, to request to be appointed as Lead Plaintiff for the class [2] Group 2: Company Background - Cepton is an electronics company focused on high-performance lidar technologies for the Automotive and Smart Infrastructure markets, offering various lidar systems and software [4] - Koito Manufacturing Co., Ltd. invested $200 million in Cepton in July 2023, acquiring 30.1% of Cepton's voting power and two board seats [5] Group 3: Merger Information - Cepton accepted Koito's bid of $3.17 per share in July 2024, which closed on January 7, 2025, providing cash to all outstanding Cepton shareholders [6] - The merger was described as a strategic milestone for Cepton, aimed at enhancing its lidar technology commercialization [6] Group 4: Allegations in the Complaint - The Complaint alleges that Cepton's executives made materially false and misleading statements regarding the company's operations and compliance, including failing to disclose a credible third-party bid valuing Cepton at more than double the Koito Acquisition [6][8] - It is claimed that the Board did not adequately explore this third-party offer and misled shareholders regarding the terms of the Koito Acquisition [6][8] - Allegations also include conflicts of interest involving Cepton's CEO, who is said to have prioritized personal economic interests over those of the shareholders [8]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of NuScale Power Corporation regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] - Citigroup downgraded NuScale from Neutral/High Risk to Sell/High Risk on October 21, 2025, citing competition from new entrants and the lack of a binding customer contract [2] - Following the downgrade, NuScale's stock price fell by $9.49 per share, or 21.47%, closing at $34.72 per share on October 22, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Alector, Inc. following disappointing clinical trial results for its drug, latozinemab, which did not meet primary endpoints [1][2]. Group 1: Company Overview - Alector, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases [2]. - The company recently announced results from the Phase 3 INFRONT-3 clinical trial for latozinemab, which targets frontotemporal dementia due to a progranulin gene mutation [2]. Group 2: Clinical Trial Results - The Phase 3 clinical trial results indicated that latozinemab failed to meet its clinical co-primary endpoint of slowing the progression of frontotemporal dementia [2]. - Secondary and exploratory endpoints, including fluid biomarkers and volumetric magnetic resonance imaging (vMRI), showed no treatment-related effects [2]. Group 3: Market Reaction - Following the announcement of the trial results, Alector's stock price dropped by $1.60 per share, representing a decline of 49.84%, closing at $1.61 per share on October 22, 2025 [2].

Core Viewpoint - American Battery Technology Company is under investigation for potential securities fraud following the termination of a significant grant from the U.S. Department of Energy, which has led to a substantial decline in its stock price [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of American Battery Technology Company regarding possible securities fraud or unlawful business practices by the company and its officers/directors [1]. - The investigation was prompted by the disclosure that the U.S. Department of Energy terminated a grant that would have provided $57.7 million for the construction of a commercial scale facility for manufacturing battery cathode grade lithium hydroxide [2]. Group 2: Financial Impact - Following the announcement of the grant termination, American Battery's stock price dropped by $6.48 per share, representing a 57.19% decline, closing at $1.85 per share on October 17, 2025 [2].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving United Homes Group, Inc. (UHG) and its officers or directors [1]. Group 1: Company Developments - On October 20, 2025, six board members of UHG resigned after Executive Chairman Michael Nieri refused to step down or forgo future compensation, despite a special committee's recommendation for strategic changes [2]. - Following the board resignations, UHG's stock price dropped by $2.24 per share, a decline of 52.46%, closing at $2.03 per share on the same day [2]. Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of advocating for victims of securities fraud and corporate misconduct [3].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Jumia Technologies AG regarding potential securities fraud or unlawful business practices [1] - Aletheia Capital downgraded Jumia from Buy to Sell due to concerns about its net working capital position, considering recent improvements as temporary and unsustainable [2] - Following the downgrade, Jumia's ADR price fell by $1.13, or 9.51%, closing at $10.75 on October 17, 2025 [2] Company Overview - Jumia Technologies AG is listed on the NYSE under the ticker JMIA and operates in the e-commerce sector [1] - The company has faced scrutiny regarding its financial practices and stock valuation compared to peers [2] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering significant damages for victims of securities fraud [3]